Immunogenicity and safety of SARS-CoV-2 recombinant protein subunit vaccine (IndoVac) adjuvanted with alum and CpG 1018 in Indonesian adults: A phase 3, randomized, active-controlled, multicenter trial

CONCLUSIONS: IndoVac in adults showed favourable safety profile and elicited non-inferior immune response to Covovax. (ClinicalTrials.gov: NCT05433285, Indonesian Clinical Research Registry: INA-R5752S9).PMID:38575433 | DOI:10.1016/j.vaccine.2024.03.077

Source: Vaccine - April 4, 2024 Category: Allergy & Immunology Authors: Asrawati Nurdin Yetty Movieta Nency Martira Maddeppungeng Rini Sekartini Rini Mulia Sari Fikrianti Surachman Finny Fitry Yani None Raveinal Fenty Anggrainy Al Hafiz None Linosefa Rizanda Machmud Putri Awaliyah Deza Vovinda Rujiana Martga Bella Rahimi Nur Source Type: research